Mark Yarchoan, MD

Primary Academic Title

Associate Professor of Oncology

Background

Centers and Institutes

• Bloomberg~Kimmel Institute for Cancer Immunotherapy
• Liver and Biliary Cancer Multidisciplinary Clinic
• Pancreatic Cancer Precision Medicine Center of Excellence
• Sidney Kimmel Comprehensive Cancer Center
• Skip Viragh Center for Pancreatic Cancer

X (Twitter)

https://twitter.com/MarkYarchoan

Clinical Trial Keywords

Hepatocellular Carcinoma (HCC); Biliary tract cancer (BTC); Cholangiocarcinoma; Liver Cancer; Immunotherapy; Fibrolamellar hepatocellular carcinoma (FLC)

Clinical Trials Summary

GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer Pancreatic Cancer

DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma Fibrolamellar Hepatocellular Carcinoma (FLC)

A multicenter Phase 2 of atezolizumab with or without cobimetinib in patients with advanced biliary tract cancer, conducted through the NCI Experimental Therapeutics Clinical Trials Network (ETCTN) Study. Role: Co-PI

A single center neoadjuvant study of cabozantinib plus nivolumab in patients with potentially resectable hepatocellular carcinoma (HCC). Role: PI

A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer. Role: Co-PI

A study of perioperative nivolumab with or without relatlimab in patients with resectable hepatocellular carcinoma (HCC). Role: PI

Google Scholar

https://scholar.google.com/citations?user=iw1kBoAAAAAJ&hl=en

PubMed

http://www.ncbi.nlm.nih.gov/myncbi/browse/collection/46440227/

Selected Publications

• Yarchoan M, Cope L, Anders RA, Noonan A, Goff LW, Goyal L, Lacy J, Li D, Patel A, He AR, Abou-Alfa G, Spencer K, Kim E, Xavier S, Ruggieri A, Davis SL, McRee A, Kunk P, Zhu Q, Wang-Gillam A, Poklepovic A, Chen H, Sharon E, Lesinski GB, Azad N. Multicenter randomized phase II trial of atezolizumab with or without cobimetinib in biliary tract cancers. J Clin Invest. 2021 Dec 15;131(24):e152670. doi: 10.1172/JCI152670

• Yarchoan M, Ho WJ, Mohan A, Shah Y, Vithayathil T, Leatherman J, Dennison L, Zaidi N, Ganguly S, Woolman S, Cruz K, Armstrong TD, Jaffee EM. Effects of B cell–activating factor on tumor immunity. JCI Insight. JCI Insight; 2020 May 21;5(10)

• Yarchoan M, Hopkins A, Jaffee EM (2017) Tumor Mutational Burden and Response Rate to PD-1 Inhibition. N Engl J Med 377: 2500–2501. PMCID: PMC6549688

• Yarchoan M, Huang C, Zhu Q, Ferguson AK, Durham JN, Anders RA, Thompson ED, Rozich NS, Thomas DL, Nauroth JM, Rodriguez C, Osipov A, De Jesus?Acosta A, Le DT, Murphy AG, Laheru D, Donehower RC, Jaffee EM, Zheng L, Azad NS (2020) A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer. Cancer Med 9: 1485–1494, doi:10.1002/cam4.2763

• Ho WJ, Zhu Q, Durham J, Popovic A, Xavier S, Leatherman J, Mohan A, Mo G, Zhang S, Gross N, Charmsaz S, Lin D, Quong D, Wilt B, Kamel IR, Weiss M, Philosophe B, Burkhart R, Burns WR, Shubert C, Ejaz A, He J, Deshpande A, Danilova L, Stein-O’Brien G, Sugar EA, Laheru DA, Anders RA, Fertig EJ, Jaffee EM, Yarchoan M. Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity. Nat Cancer. 2021 Jul 29;1–13

Honors

• ASCO Career Development Award, Conquer Cancer Foundation/ASCO, 7/1/21
• Cholangiocarcinoma Foundation Mark R. Clements Award, Cholangiocarcinoma Foundation, 7/1/21
• Director's Teaching Award in Clinical Science, 1/1/19
• Incyte Young Investigator Award for Translational Science, 1/1/19
• ASCO Young Investigator Award, Conquer Cancer Foundation, 7/1/17
• Inaugural Linda Rubin Fellowship Recipient, Johns Hopkins, 1/1/17